BUND FINANCE

BUND FINANCE › Stocks › RPRX

Royalty Pharma plc (RPRX)

NASDAQ · Stock price, chart and technical analysis

US$68.67-0.0100 (-0.01%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$68.68
OpenUS$68.73
Day rangeUS$68.32 – US$69.57
52-week rangeUS$37.31 – US$70.37
Market capUS$30.58B
Volume3.19M
50-day averageUS$61.77
200-day averageUS$54.89
Beta0.41
Last dividend per shareUS$0.9400

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$2.3BUS$2.2BUS$2.4BUS$2.3BUS$2.4B
Net incomeUS$619.7MUS$42.8MUS$1.1BUS$859.0MUS$770.9M
EPS (diluted)1.490.102.531.911.78
Gross margin100.0%100.0%100.0%100.0%100.0%
Operating margin62.5%13.7%63.4%57.1%65.6%
Net margin27.1%1.9%48.2%38.0%32.4%
Free cash flowUS$2.0BUS$2.1BUS$3.0BUS$2.8BUS$2.5B
Total debtUS$7.1BUS$7.1BUS$6.1BUS$7.6BUS$9.0B
CashUS$1.5BUS$1.7BUS$477.0MUS$929.0MUS$618.7M

Compound annual growth: revenue 1.0% · net income 5.6% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E51.6x92.0x27.1x
EV / EBITDA25.0x21.1x16.5x
Operating margin59.8%—3.6%
Net margin25.7%—-0.0%
Debt / equity1.41—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Royalty Pharma plc

SectorHealthcare
IndustryMedical - Pharmaceuticals
CountryUS
CEOPablo Legorreta
Employees100
IPO date2020-06-16

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

www.royaltypharma.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice